---
created: 2025-04-13
updated: 2025-04-13T10:53
id: wnXuwc2:!i
specialty: pharmaco
specialty_id: 328
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::02-alkylating-agents
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::13-alkylating-agents
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::13-alkylating-agents::cyclophosphamide
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::13-alkylating-agents::ifosfamide
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::07-cyclophosphamide,-ifosfamide
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::02-dna-&-cellular-division::01-cyclophosphamide,-ifosfamide,-busulfan,-nitrosoureas-(carmustine,-lomustine,-streptozocin)::zanki-extra
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary"
type: flashcard
---

# Question
Cyclophosphamide and Ifosfamide are especially suited for neoplasias of **immune** cells as well as **solid** malignancies

---

# Answer
